MetaCap

GeoVax Labs (GOVX) vs China SXT Pharmaceuticals (SXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GeoVax Labs is the larger company by market cap ($985,459 vs $273,955), about 3.6 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -37.1%). China SXT Pharmaceuticals converts more of its revenue into profit, with a net margin of -545.2% versus -862.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOVX+525.43%SXTC-6.54%
+684%+274%-136%
Oct 7, 20261 yearNov 20, 2026
GOVX+544.13%SXTC+1678.75%
+2194%+1007%-180%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOVX versus SXTC key metrics
MetricGOVXSXTC
Share price$1.81$2.65
Market cap$985.46K$273.95K
1-day change-5.24%+2.12%
EPS (TTM)$-15.03$-73,040.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.49M$1.14M
Revenue growth (YoY)-37.06%-34.63%
Net income (latest FY)$-21.46M$-6.21M
Gross margin—21.85%
Operating margin-869.34%-625.89%
Net margin-862.34%-545.24%
52-week high$270.60$8,376,000.00
52-week low$1.51$2.52
Distance from 52-week high-99.33%-100.00%
Analyst consensusnone—
Avg. price target upside+452.49%—
Average volume213.41K234.25K
Shares outstanding544.45K103.58K
Employees1956
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GeoVax Labs is about 3.6 times larger than China SXT Pharmaceuticals by market value ($985.46K vs $273.95K).
  • China SXT Pharmaceuticals is more profitable, keeping -545.2 cents of every revenue dollar as net income versus -862.3 cents for GeoVax Labs.

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About China SXT Pharmaceuticals

SXTC stock →

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

GOVX vs SXTC FAQ

Which is bigger, GeoVax Labs or China SXT Pharmaceuticals?

GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $273.95K for China SXT Pharmaceuticals (SXTC).

Are GeoVax Labs and China SXT Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons